Skip to main content

ATHE 6-K

Alterity Therapeutics Ltd (ATHE)

6-K 2025-11-24 For: 2025-11-24
View Original
Added on July 04, 2026

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-163

UNDERTHE SECURITIES EXCHANGE ACT OF 1934


Forthe month of November 24, 2025

AlterityTherapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.


Form 20-F ☒       Form 40-F ☐


ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073,333-248980 and 333-228671)and our Registration Statements on Form F-3 (Files No. 333-274816,333-251647, 333-231417and 333-250076)



ALTERITYTHERAPEUTICS LIMITED

(adevelopment stage enterprise)

The following exhibits are submitted:

99.1 Final Director’s Interest Notice - Meltzer
1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Alterity Therapeutics Limited
By: /s/ Julian Babarczy
Julian Babarczy
Chairman

Date: November 24, 2025

2

Exhibit 99.1

Appendix 3Z
Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice


Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19.A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director Brian Meltzer
Date of last notice 17 September 2025
Date that director ceased to be director 21 November 2025

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities9,415,584 - FULLY PAID ORDINARY SHARES<br><br>2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01<br><br>757,576 - LISTED OPT EXP 26/02/2027 @ $0.028<br><br>30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01

Part 2 - Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.
BT PORTFOLIO SERVICES (SMSF) 326,666 - FULLY PAID ORDINARY SHARES

Part 3 - Director’s interests in contracts


Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
No. and class of securities to which interest relates N/A
+ See chapter 19 for defined terms.
--- ---
11/03/2002 Appendix 3Z Page 1